US lawmakers urge Trump and Indian Prime Minister Modi to address IP and trade barriers

26 June 2017

Even as Indian drug firms continue to reel under plans by the Trump administration in the USA to repeal and replace some parts of The Patient Protection and Affordable Care Act, popularly known as Obamacare, four prominent US lawmakers have outlined a number of concerns, including inadequate intellectual property rights protection, reports The Pharma Letter’s India correspondent.

US House Ways and Means Committee Chairman Kevin Brady, Ranking Member Richard Neal, Senate Finance Committee Chairman Orrin Hatch and Ranking Member Ron Wyden have urged President Donald Trump to advocate for market-based reforms and eliminate trade and investment barriers during Indian Prime Minister Narendra Modi’s visit to the White House.

In a letter, the four have urged the US President to personally address India’s significant and longstanding barriers to trade and investment. Regarding IPR protection, the four Congressmen said they continue to have concerns about India's system for providing protection for patents, trademarks, and copyrights.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK